ALTSTATION.IO

Eli Lilly and Company (LLY) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$1046.28

Change

+2.49%

Market Cap

$937.94B

Avg Volume

3.4M

Company Overview

Eli Lilly and Company (LLY) is a global pharmaceutical giant based in Indianapolis, Indiana. The company discovers, develops, and markets a wide range of medications. This includes treatments for diabetes, such as Humalog and Trulicity, alongside oncology drugs like Alimta and Verzenio. Their products are sold to healthcare providers, hospitals, and pharmacies, impacting millions of patients worldwide. They also offer treatments for autoimmune diseases, depression, and obesity.

Lilly stands as a market leader in several therapeutic areas, particularly in diabetes and oncology. They face competition from other major pharmaceutical firms like Novo Nordisk, Sanofi, and Merck. Lilly’s robust portfolio of innovative therapies gives it a competitive edge, but pricing pressures and regulatory challenges remain ongoing threats. Strategic collaborations with firms like NVIDIA and Boehringer Ingelheim also help bolster their research capabilities and market position.

Currently, Eli Lilly is in a growth phase, fueled by successes in drug approvals and expanding product lines. Their recent launch of Mounjaro, a promising diabetes treatment, has shown strong revenue potential, while existing products continue to perform well. The company is actively investing in research and partnerships to enhance its offerings, indicating a clear intent to expand its footprint in emerging markets and therapeutic areas. These strategic moves set the stage for strong future performance.

Key Financials

Market Cap

$937.94B

Revenue

$65.18B

EBITDA

$31.58B

Gross Margin

83.0%

Profit Margin

31.7%

Revenue Growth

42.6%

Total Cash

$9.91B

Total Debt

$42.58B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

45.55

Forward P/E

25.20

Beta

0.39

52-Week High

$1133.95

52-Week Low

$623.78

EPS

$22.97

50-Day Avg

$1054.70

200-Day Avg

$858.34

Price/Book

39.39

Technical Analysis

Over the past 52 weeks, Eli Lilly and Company (LLY) has displayed a strong upward trend, increasing from a low around $700 to its current price of $1046.28, marking a 22.7% rise. Key support levels can be identified at approximately $800 and $900, while resistance is clear near the recent high of $1058.18, which has proven to be a barrier in late December and early February. The stock has also formed a series of higher lows and higher highs, indicating a bullish pattern overall. In recent weeks, LLY demonstrated notable momentum, breaking above its short-term resistance and showing sustained buying pressure after a minor consolidation phase. Currently sitting at approximately 98.9% of its 52-week high, the price suggests strong bullish sentiment, indicating that market participants are optimistic about future performance.

Recent News and Developments

Market Update

Eli Lilly and Company (LLY) has experienced a significant week of news and developments, largely driven by a strong fourth-quarter earnings report and an optimistic outlook for 2026. This has led to positive analyst reactions and a notable surge in its stock price.

Market Update

Here are 3-5 specific news items from the past week:

Market Update

### Eli Lilly Exceeds Q4 Earnings and Raises 2026 Guidance, Driving Stock Surge

Market Sentiment and Analyst Recommendations

Bull Case

Eli Lilly is firing on all cylinders. Q4 beat expectations with $19.3B in revenue versus $17.87B consensus, and 2026 guidance of $80-83B implies roughly 23-27% growth from current run rate. The obesity and diabetes franchise (Mounjaro, Zepbound) is the growth engine here — 42.6% revenue growth doesn’t happen without real blockbuster demand. Manufacturing expansion in Pennsylvania and elsewhere removes the supply constraint that plagued competitors, giving Lilly the capacity to capture market share for years. Orforglipron’s April 10th FDA decision is a catalyst for an oral option that could expand the addressable market beyond injectable users. Analyst consensus sits at $1,179.52 target with 27 buy ratings, and Morgan Stanley and Leerink just raised targets to $1,313 and $1,296 respectively. At current price, the risk/reward favors upside if execution holds.

Bear Case

The valuation is stretched. At 45.55x P/E with the stock at 98.9% of its 52-week high, you’re paying peak prices for a company that’s already priced in substantial growth. The $42.58B debt load against $9.91B cash is manageable but not insignificant, especially if the company needs to fund that aggressive capex expansion. Competition is real — Novo Nordisk has Ozempic and Wegovy entrenched in market, and other pharma players are developing GLP-1 alternatives. Regulatory risk exists: orforglipron’s April decision could disappoint, and obesity drug reimbursement pressures could emerge if payers push back on cost. The stock has already run 22.7% in 52 weeks. If 2026 guidance misses or obesity drug demand plateaus faster than expected, there’s significant downside from current levels. A 10-15% correction wouldn’t be shocking given the valuation.

What to Watch

April 10th FDA decision on orforglipron is the near-term catalyst — approval opens the oral market, rejection tanks the stock. Monitor Q1 2025 results for any softening in Mounjaro/Zepbound demand or pricing pressure, especially from payers. Track manufacturing capacity utilization rates and any production delays that could constrain growth. Watch competitor moves closely: Novo Nordisk’s earnings and market share data matter more now that obesity drugs are mainstream. The $1,058 resistance level from late December/early February is critical technically — a sustained break above signals continuation, while a drop below $1,000 suggests momentum is fading. Reimbursement news is a wildcard — any major payer restrictions on GLP-1 coverage would be a red flag. Finally, keep tabs on debt levels and capex spend; if the company takes on more debt to fund expansion without proportional revenue growth, the thesis weakens.

Analyst Consensus

BUY

Based on 27 analyst opinions

Low Target

$830.00

Mean Target

$1179.52

High Target

$1500.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 30, 2026

EPS (Trailing)

$22.97

Dividend Yield

61.0%

Payout Ratio

26.1%

Frequently Asked Questions

Is LLY a good stock to buy?

With a current price of $1046.28 and a market cap of $937.94B, Eli Lilly is well-positioned in the healthcare sector, particularly in drug manufacturing. Analysts rate it a BUY with a price target of $1179.52, suggesting about 13% upside potential.

What is LLY’s price target?

Analysts have set a price target of $1179.52 for Eli Lilly stock. This target reflects strong growth expectations based on its solid fundamentals and future earnings.

Does LLY pay a dividend?

Yes, Eli Lilly has a substantial dividend yield of 61.0%. This makes it an attractive option for income-focused investors, especially in a high-growth sector like healthcare.

What is LLY’s P/E ratio?

Eli Lilly’s current P/E ratio stands at 45.55, while the forward P/E ratio is 25.20. The higher P/E suggests that investors are anticipating strong earnings growth in the future.

What has been LLY’s performance in the past 52 weeks?

LLY’s stock has fluctuated between $623.78 and $1133.95 over the past year. This range highlights significant volatility, but the current price indicates a strong upward trend compared to the lower end of that spectrum.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.